5 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 5 of 5 clinical reviews.
Current regulatory and compounding status of PT-141 (bremelanotide), including FDA approval history, Vyleesi labeling, 503A/503B compounding rules, and post-market safety data.
A detailed review of bremelanotide (Vyleesi) FDA adverse event reports, FAERS safety signals, labeling updates, and post-market surveillance findings for clinicians and patients.
A complete review of bremelanotide (Vyleesi) regulatory approvals, FDA labeling, global scheduling, and post-market safety data for hypoactive sexual desire disorder in premenopausal women.
A comprehensive review of FDA label changes for PT-141 (bremelanotide, Vyleesi) from initial approval through 2026, including safety updates, boxed warning revisions, and post-market surveillance findings.
A clinical review of bremelanotide (Vyleesi/PT-141) legal history, patent disputes, FDA regulatory pathway, label requirements, and ongoing post-market safety obligations.